Politico interviewed Horizon’s Joel White about telehealth platforms and pharmaceutical companies battling to offer groundbreaking weight-loss drugs for the cheapest price possible.
While Novo’s and Lilly’s drugs were subject to years of research and FDA-approved clinical trials in patients, the same can’t be said for compounded drugs, said Joel White, a Republican health lobbyist who worked on the 2013 law. Changing dosage levels and adding vitamins, he said, is “how you end up with a New England-type situation.”